



## Company Overview

Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

## Abeona Therapeutics to Present at Upcoming Investor Conferences

Sep 7 2021, 7:30 AM EDT

## Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer

Aug 10 2021, 7:30 AM EDT

## Abeona Therapeutics Reports Second Quarter Financial Results

Jul 28 2021, 4:01 PM EDT

## Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	121.47m
Last Price	\$1.20
52-Week	\$0.9895 - \$3.7899

09/17/2021 04:00 PM EDT

## Investor Relations

[ir@abeonatherapeutics.com](mailto:ir@abeonatherapeutics.com)

## Management Team

### Michael Amoroso

President, Chief Executive Officer

### Vishwas Seshadri, Ph.D., M.B.A.

Senior Vice President, Head of Research & Clinical Development

### Edward Carr

Chief Financial Officer, Principal Financial Officer

### Greg Gin

Vice President, Investor Relations and Corporate Communications

### Brian Kevany, Ph.D.

Vice President, Manufacturing and Interim Head of Quality & Technical Operations

### Kristina Maximenko

Vice President, Human Resources

### Scott Nogi

Vice President, Business Operations

### Brendan O'Malley, J.D., Ph.D.

Vice President, Head of Legal and IP

## Abeona Therapeutics Inc.

1330 Avenue of the Americas  
33rd Floor  
New York, NY 10019

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.